GlassScriptPhysician profile
Colin W Weerts
NPI 1245597046
$1,054.82
in general payments reported to CMS, 2019-2025
35 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $40.55 · 2021: $156 · 2022: $146 · 2023: $145 · 2024: $222 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62.02 | 2021-2025 | Qulipta |
| Radius Health, INC. | $56.55 | 2021-2024 | Tymlos |
| Exact Sciences Corporation | $52.31 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $52.15 | 2021-2024 | Eohilia |
| Pfizer INC. | $52.14 | 2021-2024 | |
| Lilly USA, LLC | $47.55 | 2019-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $47.54 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $44.47 | 2019-2025 | Austedo Xr, Ajovy |
| Biogen, INC. | $43.73 | 2019 | |
| Astellas Pharma US INC | $43.55 | 2023-2025 | Veozah, Myrbetriq |
| Grifols USA, LLC | $40.82 | 2019-2023 | Prolastin-C Liquid |
| Ironwood Pharmaceuticals, INC | $34.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $34.88 | 2023-2024 | Verquvo, Dificid, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.03 | 2021-2022 | |
| Harmony Biosciences LLC | $30.97 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $30.86 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.58 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $28.18 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.43 | 2019-2025 | Eliquis |
| Daiichi Sankyo INC. | $25.44 | 2022 | |
| Axonics, INC. | $21.42 | 2023 | Axonics |
| Abbott Laboratories | $21.04 | 2024 | Freestyle Libre 3 |
| Medtronic, INC. | $19.23 | 2025 | Inceptiv |
| Xeris Pharmaceuticals, INC. | $18.56 | 2024 | Keveyis |
| Ironshore Pharmaceuticals INC. | $18.52 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.06 | 2022 | |
| Dexcom, INC. | $16.07 | 2023 | Dexcom G6 Transmitter |
| Corium, LLC | $15.53 | 2024 | Azstarys |
| Viatris Specialty LLC | $13.85 | 2025 | Yupelri |
| Amarin Pharma, INC. | $13.65 | 2021 | |
| Kyowa Kirin, INC. | $13.30 | 2024 | Crysvita |
| Philips North America LLC | $12.78 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.37 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.24 | 2019 | |
| Mylan Specialty L.P. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Weerts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.